Showing results (1-10 of 279) with videos related to
Sort By:
Pageof 28
Expert Opinion on Investigational Drugs|September 28, 2005
Targeted therapy in renal cell carcinomaJustin P Favaro, Daniel J GeorgeUrology|September 17, 2002
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylateDaniel J GeorgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinomaDaniel J GeorgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Tyrosine kinase inhibitors in renal cell carcinomaAnil Potti, Daniel J GeorgeAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 30, 2021
Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority PopulationsMatthew Labriola, Daniel J GeorgeFuture Oncology (London, England)|August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancerDaniel J George, David P DearnaleyTherapeutics and Clinical Risk Management|May 14, 2008
Satraplatin in the treatment of hormone-refractory metastatic prostate cancerAndrew J Armstrong, Daniel J GeorgeCurrent Opinion in Urology|April 9, 2005
Update in the management of patients with hormone-refractory prostate cancerCassandra N Moore, Daniel J GeorgeCancer Treatment Reviews|February 2, 2010
Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial dataDavid F McDermott, Daniel J GeorgeBMC Cancer|May 8, 2015
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case reportMegan A McNamara, Daniel J GeorgePageof 28